Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Karyopharm Therapeutics in a report issued on Wednesday, February 26th. HC Wainwright analyst E. White now forecasts that the company will post earnings of ($4.37) per share for the quarter, down from their previous estimate of ($4.35). HC Wainwright currently has a "Buy" rating and a $56.00 price target on the stock. The consensus estimate for Karyopharm Therapeutics' current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics' Q2 2025 earnings at ($4.19) EPS, Q3 2025 earnings at ($3.39) EPS, Q4 2025 earnings at ($3.81) EPS, FY2025 earnings at ($15.63) EPS, FY2026 earnings at ($11.15) EPS and FY2027 earnings at ($9.05) EPS.
Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.90) by $0.30. The business had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million.
KPTI has been the subject of several other reports. Royal Bank of Canada reiterated an "outperform" rating and issued a $45.00 price objective on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. Piper Sandler raised their price target on shares of Karyopharm Therapeutics from $60.00 to $75.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. Finally, StockNews.com cut shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, November 22nd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $62.75.
Check Out Our Latest Stock Analysis on KPTI
Shares of KPTI opened at $7.95 on Monday. The stock has a 50 day simple moving average of $9.81 and a 200 day simple moving average of $11.24. Karyopharm Therapeutics has a 52-week low of $7.61 and a 52-week high of $25.50. The firm has a market capitalization of $66.94 million, a PE ratio of -7.79 and a beta of 0.06.
Several hedge funds have recently made changes to their positions in KPTI. Adage Capital Partners GP L.L.C. grew its stake in shares of Karyopharm Therapeutics by 46.3% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company's stock worth $4,274,000 after acquiring an additional 2,000,000 shares in the last quarter. GSA Capital Partners LLP grew its stake in shares of Karyopharm Therapeutics by 80.6% in the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock valued at $1,474,000 after buying an additional 792,283 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Karyopharm Therapeutics by 265.5% in the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company's stock valued at $506,000 after buying an additional 543,556 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Karyopharm Therapeutics by 15.3% in the fourth quarter. Marshall Wace LLP now owns 2,401,413 shares of the company's stock valued at $1,633,000 after buying an additional 319,187 shares in the last quarter. Finally, Shay Capital LLC bought a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at $116,000. 66.44% of the stock is owned by institutional investors.
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Karyopharm Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Karyopharm Therapeutics wasn't on the list.
While Karyopharm Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.